Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

M. Joerger; D. Dejong; A. Burylo; J.A. Burgers; P. Baas; AD Huitema; J.H. Beijnen; J.H.M. Schellens

Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

M. Joerger, D. Dejong, A. Burylo, J.A. Burgers, P. Baas, AD Huitema, J.H. Beijnen, J.H.M. Schellens

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced NSCLC receiving platinum-gemcitabine chemotherapy. METHODS: Quantitative PCR or immunohistochemistry were used to analyze the expression of beta-tubuline IIA (TUBB2A), beta-tubuline III (TUBB3), BRCA1, ERCC1, Abraxas (ABRX) and RAP80 in mRNA isolated from paraffin-embedded tumor biopsies of 45 NSCLC patients treated as part of a larger observational trial. All patients received first-line platinum-gemcitabine chemotherapy for stage IIIB or IV NSCLC. RESULTS: Median progression-free survival (PFS) was 7 months, overall survival (OS) 12 months. A partial treatment response was found in 14 patients (33%). Patients with low ERCC1 or ABRX expression had a significantly better response to chemotherapy (R=-0.45, p

Original language	Undefined/Unknown
Pages (from-to)	310-7
Number of pages	8
Journal	Lung Cancer
Volume	74
Issue number	2
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{b6307ab957524fa4b23d93a3bc39652a,

title = "Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.",

abstract = "BACKGROUND: The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced NSCLC receiving platinum-gemcitabine chemotherapy. METHODS: Quantitative PCR or immunohistochemistry were used to analyze the expression of beta-tubuline IIA (TUBB2A), beta-tubuline III (TUBB3), BRCA1, ERCC1, Abraxas (ABRX) and RAP80 in mRNA isolated from paraffin-embedded tumor biopsies of 45 NSCLC patients treated as part of a larger observational trial. All patients received first-line platinum-gemcitabine chemotherapy for stage IIIB or IV NSCLC. RESULTS: Median progression-free survival (PFS) was 7 months, overall survival (OS) 12 months. A partial treatment response was found in 14 patients (33%). Patients with low ERCC1 or ABRX expression had a significantly better response to chemotherapy (R=-0.45, p",

author = "M. Joerger and D. Dejong and A. Burylo and J.A. Burgers and P. Baas and AD Huitema and J.H. Beijnen and J.H.M. Schellens",

year = "2011",

language = "Undefined/Unknown",

volume = "74",

pages = "310--7",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd.",

number = "2",

}

Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. / Joerger, M.; Dejong, D.; Burylo, A. et al.
In: Lung Cancer, Vol. 74, No. 2, 2011, p. 310-7.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

AU - Joerger, M.

AU - Dejong, D.

AU - Burylo, A.

AU - Burgers, J.A.

AU - Baas, P.

AU - Huitema, AD

AU - Beijnen, J.H.

AU - Schellens, J.H.M.

PY - 2011

Y1 - 2011

N2 - BACKGROUND: The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced NSCLC receiving platinum-gemcitabine chemotherapy. METHODS: Quantitative PCR or immunohistochemistry were used to analyze the expression of beta-tubuline IIA (TUBB2A), beta-tubuline III (TUBB3), BRCA1, ERCC1, Abraxas (ABRX) and RAP80 in mRNA isolated from paraffin-embedded tumor biopsies of 45 NSCLC patients treated as part of a larger observational trial. All patients received first-line platinum-gemcitabine chemotherapy for stage IIIB or IV NSCLC. RESULTS: Median progression-free survival (PFS) was 7 months, overall survival (OS) 12 months. A partial treatment response was found in 14 patients (33%). Patients with low ERCC1 or ABRX expression had a significantly better response to chemotherapy (R=-0.45, p

AB - BACKGROUND: The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced NSCLC receiving platinum-gemcitabine chemotherapy. METHODS: Quantitative PCR or immunohistochemistry were used to analyze the expression of beta-tubuline IIA (TUBB2A), beta-tubuline III (TUBB3), BRCA1, ERCC1, Abraxas (ABRX) and RAP80 in mRNA isolated from paraffin-embedded tumor biopsies of 45 NSCLC patients treated as part of a larger observational trial. All patients received first-line platinum-gemcitabine chemotherapy for stage IIIB or IV NSCLC. RESULTS: Median progression-free survival (PFS) was 7 months, overall survival (OS) 12 months. A partial treatment response was found in 14 patients (33%). Patients with low ERCC1 or ABRX expression had a significantly better response to chemotherapy (R=-0.45, p

M3 - Article

SN - 0169-5002

VL - 74

SP - 310

EP - 317

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -